Sprint Bioscience AB (publ) (STO:SPRINT)

Market Cap	397.79M +812.8%
Revenue (ttm)	153.28M +145.7%
Net Income	84.49M
EPS	0.82
Shares Out	105.52M
PE Ratio	4.57
Forward PE	12.96
Dividend	n/a
Ex-Dividend Date	n/a

Volume	335,851
Open	3.640
Previous Close	3.680
Day's Range	3.590 - 3.790
52-Week Range	0.415 - 4.210
Beta	-0.51
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About Sprint Bioscience AB

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 30
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SPRINT